gene therapy

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report
Endpoints
Sun, 06/16/19 - 11:19 pm
uniQure
M&A
gene therapy
Gene therapy costs, manufacturing keeping CBER head 'up at night'
Biopharma Dive
Thu, 06/13/19 - 09:47 pm
gene therapy
CBER
drug manufacturing
The gene therapy era has arrived. So have the challenges.
Biopharma Dive
Sun, 06/9/19 - 01:43 pm
cell therapy
gene therapy
FDA
regulatory
Novartis
Zolgensma
Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
Motley Fool
Sun, 06/9/19 - 01:41 pm
gene editing
gene therapy
DMD
Duchenne Muscular Dystrophy
Vertex Pharmaceuticals
CRISPR Therapeutics
Exonics
Vertex sets sights on DMD gene therapy, joining crowded field
Biopharma Dive
Fri, 06/7/19 - 10:17 am
Vertex Pharmaceuticals
DMD
M&A
CRISPR Therapeutics
Exonics
gene therapy
Patients, payers await pricing plans for bluebird's first approved gene therapy
BioCentury
Tue, 06/4/19 - 11:04 am
Bluebird Bio
gene therapy
Zynteglo
drug pricing
beta thalassemia
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval
Xconomy
Mon, 06/3/19 - 07:50 pm
Bluebird Bio
gene therapy
Europe
Zynteglo
EMA
beta thalassemia
Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
Motley Fool
Fri, 05/31/19 - 11:53 pm
Novartis
Zolgensma
SMA
gene therapy
Amicus widens UPenn gene therapy collaboration
Biopharma Dive
Wed, 05/29/19 - 10:35 pm
Amicus Therapeutics
UPenn
gene therapy
Galafold
Fabry disease
How BioMarin May Revolutionize the Hemophilia Treatment Market
Motley Fool
Tue, 05/28/19 - 11:25 pm
Biomarin
gene therapy
hemophilia A
valrox
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Yahoo/Reuters
Thu, 05/23/19 - 09:48 am
Novartis
Pharma CEOs
Vas Narasimhan
gene therapy
SMA
drug pricing
Zolgensma
UniQure snags patents on Huntington's gene therapy as it preps for the clinic
Biopharma Dive
Wed, 05/22/19 - 09:06 pm
uniQure
gene therapy
Huntington's disease
clinical trials
AMT-130
David Hallal brings his first cell therapy company into the fold, and it's tied to a major league financing deal
Endpoints
Wed, 05/22/19 - 09:53 am
David Hallal
ElevateBio
cell therapy
gene therapy
AlloVir
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
CNBC
Fri, 05/17/19 - 07:21 pm
gene therapy
cancer
Novartis
Pharma CEOs
Vas Narasimhan
GenSight’s Eye Disease Gene Therapy Shows Sustained Vision Improvement
BioSpace
Wed, 05/15/19 - 11:35 pm
Gensight Biologics
clinical trials
gene therapy
LHON
ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups
Xconomy
Mon, 05/13/19 - 09:34 am
ElevateBio
gene therapy
cell therapy
Bluebird's not looking to break speed records with its first gene therapy launch
Fierce Pharma
Fri, 05/10/19 - 12:48 pm
Bluebird Bio
gene therapy
beta thalassemia
Zynteglo
drug launches
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
Endpoints
Tue, 05/7/19 - 06:54 pm
Verve Therapeutics
Sekar Kathiresan
gene therapy
Novartis makes final Zolgensma pitch before FDA decision
BioPharma Dive
Sun, 05/5/19 - 06:51 pm
Novartis
gene therapy
Zolgensma
FDA
spinal muscular atrophy
Highlights: American Society of Gene & Cell Therapy Meeting
BioSpace
Fri, 05/3/19 - 10:54 pm
gene therapy
cell therapy
Audentes Therapeutics
MaxCyte
Moderna Therapeutics
Translate Bio
Homology Medicines

Pages